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Summary
We have identified cell surface receptors for Act-2, a secreted protein expressed upon activation
of T cells, B cells, and monocytes. Although 'III-Act-2 showed little, if any, specific binding
to resting peripheral blood lymphocytes (PBL) receptors were readily detected on PHA/PMA-
activated PBL and a variety of cell lines including MT2, HL60, DMSO differentiated HL60,
HeLa, and K562 cells. The equilibrium dissociation constant (Kd) is 3-12 nM for MT2, K562,
and PBL activated with PHA/PMA for 40-80 h. We have also identified a rabbit polyclonal
antiserum that can block Act-2 binding to its receptors. The ability to detect specific Act-2 receptors
and the development of a blocking antiserum should prove valuable in efforts to molecularly
clone the Act-2 receptor and to dissect the biological actions of Act-2.
A
ct-2 is a small secreted protein that belongs to a super-
family of structurally related proteins (Fig. 1). Act-2
mRNA is induced in T cells, B cells, and monocytes after
activation with mitogenic stimuli; however, this gene is not
expressed by all proliferating cells, as evidenced by its nonex-
pression in various cell lines and in serum-stimulated human
fibroblasts (1). Thus, its expression may be relatively restricted
to certain hematopoietic lineages. Act-2 is an early activation
gene with mRNA levels being detected in normal PBL within
15-30 min of activation with PHA with peak expression at
4 h. Act-2mRNA contains in its 3' untranslated region char-
acteristic AT rich sequences (1) found in a number ofproto-
oncogenes and cytokines, which appear to be involved in
regulating mRNA stability (2, 3). Other groups have also
identified cDNAs corresponding to the Act-2 gene (denoted
nF1400 [4J, PAT744 [5], and G-26 [6]) and have shown that
its expression is inhibited by Cyclosporin A (5), analogous
to a number of cytokines and early activation genes. By
analogy, therefore, the Act-2 protein may play an important
role in immune cell function.
We havepreviously determinedthat Act-2 encodes a secreted
protein, which we hypothesized to be a cytokine (1). In par-
tial support of this hypothesis, some members of the super-
family of small secreted proteins (Fig. 1) are known to be
mediators ofinflammation or to have mitogenic activity (7).
Particularly striking is the amino acid homology between
Act-2 and the a and 0 chains of murine MIP-1 (macrophage
inflammatory protein)' (71 and 77%, respectively; reference
' Abbreviations used in this paper: BB, binding buffer; MIP-1, macrophage
inflammatory protein 1; RP, reversed-phase; SCI, stem cell inhibitor.
7). We therefore hypothesize that Act-2 may represent the
human equivalent of MIP-1a orf3. Natural MIP-1 is among
the most abundant proteins synthesized after LPS stimula-
tion of macrophages. It has been reported to induce an oxi-
dative burst in neutrophils, to cause local inflammation and
neutrophil infiltration ifinjected subcutaneously in the foot-
pads of mice, to be a prostaglandin-independent endogenous
pyrogen, and to have a myelopoietic enhancing activity on
bone marrow granulocyte/macrophage progenitor cells (8).
Recently it has been reported that a reversible inhibitor of
hematopoietic stem cell proliferation, denoted SCI, has the
same amino acid sequence as MIP-la (9).
To begin to address the potential role of Act-2 in the inflam-
matory process, we purified to homogeneity recombinant
Act-2 protein and performed binding experiments in order
to investigate for the presence of cell surface receptors for
Act-2. We herein report the identification of specific Act-2
receptors (Act-2Rs) and an antiserum capable ofblocking Act-2
binding to cells.
Materials and Methods
Cell Cultures.
￿
Humancell lines: HL60, K562,MT-2, and HeLa,
were grown at 1-5 x 105 cells/ml in RPMI 1640 medium
(Biofluids, Inc., Rockville, MD) supplemented with glutamine,pen-
icillin, streptomycin, and 10% FCS. MT-2 is an HTLV1-transformed
T cell line. Human PBLs from healthy volunteers were isolated
on lymphocyte separation media (LSM, Organon Technika, West
Chester, PA). Where indicated, PBLs were stimulated for 40 to
80 h with 0.5 lAg/ml PHA (Wellcome Reagent Ltd., Beckenham,
England) and 50 ng/mlPMA (Sigma Chemical Co., St. Louis, MO).
Purification ofAct-2.
￿
The Act-2 cDNA was expressed in a bacu-
lovirus expression system using infected SF9 insect cells (1). The
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------------ ---
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------------------------
KTTSQ-VRP-RHITSLEVIKA-GP
KTTSG-INP-RHISSLEVIGA-GT
TSS-RIHL-KRITSLEVIKA-GP
IKTTSG-IHP-KNIQSLEVIGK-GT
ISISNQPVNP-RSLEKLEIIPA-SO
QTLQG-IHP-KNIQSVNVKSP-GP
QTMTG-VHL-KNIESLKVTPP-GP
QTMAG-IHL-KNIQSLKVLPS-GP
IKTYSKPFHP-KFIKELRV-IESGP
0
ISTHSKFIHP -KSIQD-VKLTPSGP
KTLPRVDF --KNIQSLSVTPP-G .
cell supernatant was applied to a preparative (10 x 250mm) Vydac
C4 reversed-phase (RP) column in 200-ml aliquots . The column
waswashed with95% bufferA(0.1%TFA), 5% buffer B(acetoni-
trile containing 0.08% TFA) at 5 ml/min . After 15 min, the per-
cent bufferBwas changed linearly in the following order : 10 min,
30%; 40 min, 40%, 45 min, 80%; 55 min, 80% ; 60 min, 5% .
Act-2-containing fractions from several runs were pooled, concen-
trated, andpurified further using a semipreparative (4.6 x 250mm)
VydacC4 RP column . Theflow rate was 2ml/min and Act-2 was
eluted using the gradient shown in Fig. 2 A. The concentration
of Act-2wasdetermined by quantitative amino acid analysis. Purified
Act-2 was hydrolyzed with argon-purged, constant boiling 6 N
HCl containing 1% (vol/vol) phenol at 110°C for 20 h using a
Waters Associates Pico TagWork Station . Amino acids were deriva-
tized with phenyhsothiocyanate and the PPC-amino acidswere sepa-
rated by RP-HPLCusing the general procedures outlined by Waters
Associates . Data,collection and reduction were performed using
a Waters Associates 840 system.
Radiolabeling of Act-2.
￿
1-4 mCi of Na'25 1 (Amersham Corp .,
Arlington Heights, IL ; 3.7 GBq/ml, 10 mCi/100 ul) was added
to 1-5 Wg of HPLC-purified Act-2 in 1001Al phosphate buffer (PB)
pH 7.4, 50 j1 ofEnzymobeads reagent (Bio-RadLaboratories, Rich-
mond, CA), and 25 Al of 2% glucose, and incubated for 15-30
min at 22'C. "I-Act-2 was separated from free label using aG-25
spun column coated with 50nM PBpH 7.4/1%BSA. The specific
activity of "I-Act-2 was 15-40 x 106 cpm/p,g .
Binding of "'I-Act-2 to Cells .
￿
Cells were washed three times
with RPMI 1640 medium/1% BSA(binding buffer, BB) and2-5 x
106 cells resuspended in 100 or 200 ul ofBB containing increasing
concentrations of '251-Act-2 for 2 h at 4°C. Nonspecific binding
was assessed by incubating samples in the presence of 100-300-fold
excess unlabeled Act-2.Each sample was layered on top of a300-Al
FCScushion and centrifuged to remove theunbound labeledhgand .
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QP-AWF-QTKRSKQ
QP-AVVF-QTKRSKQ
KP-GVIF-LTKRGRQ
KP-AWF-LTKRGRQ
NP-AVVF-VTRKNRQ
QP-GAIF-LTKRGRQ
QP-GVIF-LTKRGRQ
KP-AWF-LTKRGRQ
DPPAVVFRLNK-GRE
KE-AVIF-KTIVAKE
KE-AWF-VTKLKRE
---------------
TA-QLIATL-KNGRK
SP-QLLATK-KTGRK
VP-QLIATL-KNGSK
QV-EVIATL-KDGRKI
RV-EIIATMKKKGEK
QT-EVIATL-KNGRK
QT-EVIATL-KNGQE
QT-EVIATL-KNGRE
T-EIIVKL-SDGRE
NV-EVIATL-KDGRE
Figure 1 .
￿
Family of related proteins . Sequences above the dashed line have two adjacent cysteines, whereas those below have one amino acid
between the two cysteines. Conserved cysteines are boxed.
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DLQAPLYKK-II-KKLLES
QQRPLYKK-IL-KKLLDGDES
DRQVPLYKK-II-KKLLES
DPDAPRIKK-IVQKKLAGDESAD
NPESKAIKNL-L-KAVSKEMS . .
NPASPIVKK-IIEKMLNSDKSN
NPEAPMVQK-IVQKMLKSGIRK
DPEAPLVQK-IVQKMLKGVPK
DPKENWVQR-VVEKFLKRAENS
DPTAPWVQ-LIV-KALMAKAQLN
The pellet was washed once with BB and counted in a gamma
counter. Within each experiment, all samples were performed in
duplicate. Binding data were analyzed using the LIGAND com-
puter program (10) .
Time Course of Association .
￿
2.5 x 106 MT-2 cells were in-
cubated in BB at 4°C with 2 nM'25I-Act-2 in the presence or ab-
sence of300 nM unlabeledAct-2 . At different time points, aliquots
were centrifuged through a 300-Fl FCScushion (8,000 g for 1 min)
and the pellets were counted .
Time Course of Dissociation .
￿
2.5 x 106 MT-2 cells were in-
cubated for 2 h at4°Cwith 2 nM'lI-Act-2, washed once in sup-
plementedmedia, and resuspended in the same volume ofBB con-
taining 20 1Lg of unlabeled Act-2 to prevent reassociation of the
Figure 2 .
￿
Purification of Act-2 . (A) Act-2 was isolated as a single
peak on HPLC . (B) Silver stain of Act-2 protein electrophoresed on a
12.5% SDS polyacrylamide gel . (C) Western blot analysis using
anti-Act-2 antisera R441 (lane 1) or preimmune antisera (lane 2) .Results
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labeled ligand after dissociation. At various times, aliquots were
centrifuged through an FCS cushion.
Homologous Displacement Experiment.
￿
4 x 106 cells in 100 tt,l
of BB were bound at 1.6 nM "I--Act-2 for 2 h at 40C in the pres-
ence of0.16-300nM unlabeled Act-2 or 50-300 nM human IL ci
or íL2. All samples were tested in duplicate in each experiment.
Identification ofAntiAct-2Rabbit Antisera.
￿
Act-2 peptides cor-
responding to the entire 69 amino acids (aa) or to as -1 to +11
or to as -56 to +69 of the Act-2 protein were chemically synthe-
sized on an Applied Biosystems (Foster City, CA) Model 4300
automated peptide synthesizer using tBOC chemistry. The NH2-
and COON-terminal peptides were synthesized with an N-chlo-
roacetylglycylglycine residue and coupled to BSA that had been
reacted with iminotholane (11). Thefull-length Act-2protein (not
coupled to a carrier protein) was injected into rabbits according
to standard methods. Antisera from immunizedrabbits were evalu-
ated for their ability to recognize Act-2 in Western blotting and
immunoprecipitation experiments.
Radiolabeling of Act-2 and Detection ofAct-2Rs.
￿
Recom-
binant Act-2 was purified by HPLC (Fig. 2 A). When elec-
trophoresed and analyzed by silver staining (Fig. 2 B) or
Western blotting (Fig. 2 G), the material migrated as a dis-
crete band of -13 kD, consistent with the size previously
reported (1). Act-2 was iodinated to a specific activity of 15-40
x 106 cpm/Fig and used in binding studies in the presence
or absence of 100-300 molar excess of unlabeled Act-2.
Saturable binding curves were obtained using PHA/PMA-
activated PBL and MT-2 cells (Fig. 3, A, B). Other cell lines
such as HeU, K562, HL60, and DMSO-differentiated HL60,
also expressed specific Act-2 binding (data not shown).
ScatchardAnalyses.
￿
To determine thereceptor number and
affinity, we performed Scatchard analyses of binding data.
Binding of 1Z5í-Act-2 was carried out at 4°C for 2 h (by
which time equilibrium is achieved) in the presence or ab-
sence of unlabeled Act-2. Specific binding was determined
anddata were used to derive the equilibrium dissociation con-
stant (Kd) . For MT-2, K562, and PHA/PMA activated
1251-Act-2 added (cpm x 10-3)
￿
1251-Act-2 added (cpm x 10-3)
Figure 3.
￿
Identification of Act-2 receptors. Saturable binding of l25í-Act-2 to PHA/PMA-activated PBL (A) and MT-2 cells (B). Scatchard
analysis of A and B are shown in the insets. Total, specific, and nonspecific binding are indicated. The binding was performed at 4°C for 2 h.
The concentration of Act-2 ranged between 1 and 20 nM. The Kd was 8-12 nM.
PBLs, Scatchardplots indicatedasingle classofreceptors with
a calculated Kd of 7.8-12 x 10-9 M and the number of
receptors/cell ranging between 7,000and 10,000 in MT-2 (Fig.
3 B, inset) and K562 cells (not shown), and 45,000 in PBL
activated with PHA/PMA for 80 h (Fig. 2A, inset). In two
separate experiments, PBLactivatedwith PHA/PMAfor40
or 60 h were found to express -10,000receptor sites per cell.
This numerical difference may simply reflect theuseofdifferent
donors in each experiment. Resting PBL instead showed at
most only a smallpercentage ofAct-2bindingto PHA/PMA
Time (min) Ab dilution
C
Figure 4.
￿
(A) Displacement curve using 1.6 nM 1Z5í-Act-2 and in-
creasing concentration of unlabeled Act-2. Unlabeled Act-2, but not
ILla or 11,2, inhibited binding of 1251-Act-2 to MT-2 cells. (B) Time
course of association. MT-2 cells were incubated with 2 nM 125I-
Act-2, at 40C for 5-180 min. Samples were tested in duplicate and in
the presence and absence of 200-fold excess unlabeled Act-2. (C)
Pretreatment of 1251-Act-2 with rabbit antisera raised against the en-
tire 69 amino acid long Act-2 peptide (R441) inhibits 1251-Act-2
binding to MT-2 cells at 1:40,000 to 1:40 dilutions. (D) R441 an-
tisera, but not R461, R473, and R480 antisera, inhibited Act-2
binding to MT-2 cells at 1:40 dilutions.
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duced upon activation.
Displacement Binding Studies. To evaluate whether the
affinity of Act-2 for its receptor was modified by the iodina-
tion process, we performed binding studies using a constant
amount of labeled ligand (1.6 nM) and increasing amounts
ofunlabeled Act-2. We couldthen draw a displacement curve
(Fig. 4 A, Ligand program, reference 10) and compare the
binding patterns generated using the labeled and unlabeled
ligands. The Kd derived from Act-2 binding to MT-2 cells
in the displacement experiment was 2.8 x 10-9 M, fairly
similar to the Kd of 7.8-12 x 10-9 M calculated from the
Scatchard plots of data derived from using only labeled Act-2
(Fig. 3). We therefore concluded that iodination had little
effect on the binding of Act-2 to its receptor(s) and that the
calculated Kds were accurate.
The specificity of Act-2 binding was further demonstrated
by the inability of IL1a and IL-2 to inhibit 1251-Act-2
binding to MT-2 cells (Fig. 4 A).
Kinetic Binding Studies of "'I-Act-2 to MT2.
￿
To determine
when the binding of Act-2 to its receptor reached equilib-
rium and to independently measure the Kd, we performed
time courses of association (Fig. 4 B) and dissociation (not
shown) of Act-2 binding. Natural log plot of the data corre-
sponding to both association and dissociation kinetic studies
allowed us to calculate kinetic binding constants for dissoci-
ation (k' = 3.29 x 10-4 s-1) and association (k = 8.8 x
104 M-1s-1) and to derive the Kd as 3.7 x 10-9 M, using the
method of Wang and Smith (12). The binding reached equi-
librium by -2 h.
A Rabbit Polyclonal Antiserum Blocks Act-2 Binding.
￿
We
next evaluated ifanti-Act-2 antisera couldblock ligand binding.
One rabbit antiserum (R441) derived from immunization with
the entire 69 as Act-2 peptide blocked 1251-Act-2 binding to
its receptor. This antiserum could immunoprecipitate and im-
munoblot the Act-2 protein. The antiserum was preincubated
at 1 :40,000 to 1:40 dilution for 30 min with 5 nM 'III-
Act-2, followed by binding at 4°C to HeLa cells for 2 h. Pre-
incubation with the R441 antiserum resulted in a concen-
tration dependent inhibition of binding (Fig. 4 C). This
antiserum, therefore, may prove to be a valuable tool in
elucidating the function of the Act-2 protein. Another an-
tiserum raised against the full-length peptide (R461) and an-
tisera recognizing two shorter peptides corresponding to as
-1 to +11 (R473) and as 56 to 69 (R480) did not block
binding at the concentration tested (Fig. 4 D), despite their
ability to recognize the mature Act-2 protein by immuno-
precipitation (R461) or Western blotting (R473 and R480)
(not shown). These data suggest that the epitopes defined
by these antibodies are not part ofthe Act-2 molecule respon-
sible for binding.
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Act-2 is a small secreted protein belonging to a "superfamily"
of structurally related proteins, some members of which have
mitogenic or inflammatory activities. Based on the high de-
gree of homology and by the ability of native MIP-1, MIP-
1u, and MIP-1/3 to displace Act-2 binding to the Act-2R
(Napolitano, M., B. Sherry, and W.J. Leonard, unpublished
observation), it is attractive to hypothesize that Act-2 may
represent the human counterpart of murine MIP-1a or ,Q.
It remains to be determined ifMIP-1a and/or0 individually
possess some or all of the functional activities attributed to
MIP-1 or whether their association is required for biological
activity. By analogy, there may be the need for a coexpres-
sion of Act-2 with another factor, to obtain full biological
activity. Based on the sequence similarity, LD78 ([13], also
denoted PAT464 [5]) is a candidate for such a protein.
In this paperwe have identifiedspecific cell surface Act-2Rs
(Kd 3-12 nM). These have been detected on MT-2, HeLa,
K562, HL60, DMSO-differentiated HL60 cells, and PHA/
PMA-activated PBLs but are absent or present at low levels
in resting PBL. The marked increase in the specific binding
of 1251-Act-2 following PHA/PMA activation of PBL
strengthens the possibility that Act-2 plays a role in the cel-
lular activation process. Furthermore, both PHA/PMA
activated PBL and the MT-2 cell line thus both produce the
Act-2 protein and express cell surface receptors for Act-2, sug-
gesting the possibility that autocrine loops may occur fol-
lowing activation.
Although in comparison to a number of other cytokine/
lymphokine ligand/receptors systems, the Act-2R identified
here appears to have relatively low affinity for its ligand; it
is possible that: (a) sufficiently high concentrations ofAct-2
are achieved locally in vivo in order to obtain a functional
ligand/receptor interaction, (b) a higher affinity receptor not
yet identified may be induced on specific subsets of cell types,
or (c) an associated protein is required for Act-2 to achieve
higher affinity binding.
The multiple related gene products (Fig. 1) may represent
commonly evolved proteins, some of which may bind to shared
cellular receptors. It is possible that some of these related factors
have evolved to be induced in response to different stimuli
and may exert similar biological activities. Alternatively, it
is also possible that different target specificities may account
for diversified ranges of biological actions.
Demonstration ofspecific cellular receptors for Act-2 pro-
vides the opportunity to address the biological function of
this cytokine. A more extensive characterization of the Act-
2R and its structure will augment our knowledge on the
action of Act-2 and on post-receptor events.References
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